ANI Pharmaceuticals (NASDAQ:ANIP) Updates FY 2025 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) updated its FY 2025 earnings guidance on Saturday. The company provided earnings per share (EPS) guidance of 6.270-6.620 for the period, compared to the consensus estimate of 6.340. The company issued revenue guidance of $768.0 million-$793.0 million, compared to the consensus revenue estimate of $769.6 million.

ANI Pharmaceuticals Trading Down 2.6%

Shares of NASDAQ:ANIP traded down $1.69 during midday trading on Tuesday, hitting $63.56. The company had a trading volume of 321,986 shares, compared to its average volume of 311,834. The company has a current ratio of 2.66, a quick ratio of 1.98 and a debt-to-equity ratio of 1.46. ANI Pharmaceuticals has a 12 month low of $52.50 and a 12 month high of $77.00. The firm has a fifty day simple moving average of $64.25 and a 200 day simple moving average of $61.71. The stock has a market cap of $1.38 billion, a price-to-earnings ratio of -50.05 and a beta of 0.55.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.37 by $0.33. The firm had revenue of $197.12 million for the quarter, compared to analysts' expectations of $179.75 million. ANI Pharmaceuticals had a positive return on equity of 21.35% and a negative net margin of 3.12%. The company's revenue was up 43.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.82 earnings per share. On average, analysts predict that ANI Pharmaceuticals will post 3.86 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on ANIP shares. Wall Street Zen lowered shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. HC Wainwright restated a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. Jefferies Financial Group began coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They set a "buy" rating and a $80.00 target price on the stock. Truist Financial boosted their target price on ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a research note on Monday, April 21st. Finally, Guggenheim restated a "buy" rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a report on Monday, May 12th. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, ANI Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $80.13.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the company's stock in a transaction on Monday, April 14th. The shares were sold at an average price of $68.96, for a total value of $27,584.00. Following the transaction, the vice president directly owned 80,145 shares in the company, valued at $5,526,799.20. The trade was a 0.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Ori Gutwerg sold 881 shares of the stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $60.07, for a total transaction of $52,921.67. Following the completion of the transaction, the senior vice president directly owned 89,897 shares in the company, valued at approximately $5,400,112.79. This represents a 0.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,681 shares of company stock valued at $346,854 in the last quarter. 12.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of ANI Pharmaceuticals by 0.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company's stock worth $3,235,000 after purchasing an additional 423 shares in the last quarter. Advisors Asset Management Inc. bought a new stake in shares of ANI Pharmaceuticals in the first quarter valued at approximately $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of ANI Pharmaceuticals by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company's stock valued at $736,000 after buying an additional 470 shares during the period. Finally, Jane Street Group LLC acquired a new stake in ANI Pharmaceuticals during the first quarter worth approximately $2,706,000. Institutional investors and hedge funds own 76.05% of the company's stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.